D
Drissa Coulibaly
Researcher at University of the Sciences
Publications - 76
Citations - 4047
Drissa Coulibaly is an academic researcher from University of the Sciences. The author has contributed to research in topics: Malaria & Plasmodium falciparum. The author has an hindex of 27, co-authored 66 publications receiving 3702 citations. Previous affiliations of Drissa Coulibaly include National Institutes of Health & University of Maryland, Baltimore.
Papers
More filters
Journal ArticleDOI
A molecular marker for chloroquine-resistant falciparum malaria.
Abdoulaye A. Djimde,Ogobara K. Doumbo,Joseph F. Cortese,Kassoum Kayentao,Safi N. Doumbo,Yacouba Diourte,Drissa Coulibaly,Alassane Dicko,Xin-zhuan Su,Takashi Nomura,David A. Fidock,Thomas E. Wellems,Christopher V. Plowe +12 more
TL;DR: This study shows an association between the pfcrt T76 mutation in P. falciparum and the development of chloroquine resistance during the treatment of malaria, and this mutation can be used as a marker in surveillance forchloroquine-resistant falcIParum malaria.
Journal ArticleDOI
A field trial to assess a blood-Stage malaria vaccine
Mahamadou A. Thera,Ogobara K. Doumbo,Drissa Coulibaly,Matthew B. Laurens,Amed Ouattara,Abdoulaye K. Kone,Ando B. Guindo,Karim Traore,Idrissa Traore,Bourema Kouriba,Dapa A. Diallo,Issa Diarra,Modibo Daou,Amagana Dolo,Youssouf Tolo,Mahamadou S. Sissoko,Amadou Niangaly,Mady Sissoko,Shannon Takala-Harrison,Kirsten E. Lyke,Yukun Wu,William C. Blackwelder,Olivier Godeaux,Johan Vekemans,Marie-Claude Dubois,W. Ripley Ballou,Joe Cohen,Darby J. S. Thompson,Tina J. T. Dube,Lorraine Soisson,Carter L. Diggs,Brent House,David E. Lanar,Sheetij Dutta,D. Gray Heppner,Christopher V. Plowe +35 more
TL;DR: The malaria vaccine did not provide significant protection against clinical malaria, but on the basis of secondary results, it may have strain-specific efficacy.
Journal ArticleDOI
Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S
Aarti Agarwal,Aarti Agarwal,Aldiouma Guindo,Aldiouma Guindo,Yacouba Cissoko,Yacouba Cissoko,James G. Taylor,James G. Taylor,Drissa Coulibaly,Drissa Coulibaly,Abdoulaye K. Kone,Abdoulaye K. Kone,Kassoum Kayentao,Kassoum Kayentao,Abdoulaye A. Djimde,Abdoulaye A. Djimde,Christopher V. Plowe,Christopher V. Plowe,Ogobara K. Doumbo,Ogobara K. Doumbo,Thomas E. Wellems,Thomas E. Wellems,Dapa A. Diallo,Dapa A. Diallo +23 more
TL;DR: It is suggested that HbC does not protect against infection or uncomplicated malaria but can protect against severe malaria in the Dogon population of Bandiagara, Mali, and the protective effect associated with HBC may be greater than that of HbS in this population.
Journal ArticleDOI
Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria.
Abdoulaye A. Djimde,Ogobara K. Doumbo,Ousmane Traore,Ando B. Guindo,Kassoum Kayentao,Yacouba Diourte,Safiatou Niaré-Doumbo,Drissa Coulibaly,Abdoulaye K. Kone,Yacouba Cissoko,Mamadou Tekete,Bakary Fofana,Alassane Dicko,Dapa A. Diallo,Thomas E. Wellems,Dominic P. Kwiatkowski,Christopher V. Plowe +16 more
TL;DR: Age-adjusted comparison of subjects able to clear resistant parasites and those unable to do so provides a new phenotype for identifying host immune and genetic factors responsible for protective immunity against malaria.
Journal ArticleDOI
Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.
Mahamadou A. Thera,Ogobara K. Doumbo,Drissa Coulibaly,Dapa A. Diallo,Abdoulaye K. Kone,Ando B. Guindo,Karim Traore,Alassane Dicko,Issaka Sagara,Mahamadou S. Sissoko,Mounirou Baby,Mady Sissoko,Issa Diarra,Amadou Niangaly,Amagana Dolo,Modibo Daou,Sory I. Diawara,D. Gray Heppner,V. Ann Stewart,Evelina Angov,Elke S. Bergmann-Leitner,David E. Lanar,Sheetij Dutta,Lorraine Soisson,Carter L. Diggs,Amanda J. Leach,Alex Owusu,Marie-Claude Dubois,Joe Cohen,Jason N. Nixon,Aric L. Gregson,Shannon L. Takala,Kirsten E. Lyke,Christopher V. Plowe +33 more
TL;DR: Anti-AMA-1 antibodies increased significantly in both malaria vaccine groups, peaking at nearly 5-fold and more than 6-fold higher than baseline in the half-dose and full-dose groups, respectively.